Sun sets on Schering-Plough as Merck closes $41 billion merger
This article was originally published in Scrip
Executive Summary
Merck & Co has completed its $41 billion merger with Schering-Plough.
You may also be interested in...
Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing
Companies with market caps below $1bn continue to represent a growing percentage of biopharma deal-making, giving firms looking to license or partner assets increased optionality, Inventiv Health's Neel Patel told a session at BIO 2017.
AB Science lists on Euronext after reducing offer size
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen posts strong first-quarter sales but healthcare reform set to bite
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.